-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Cinanserin hydrochloride
Category | Influenza Virus |
CAS | 54-84-2 |
Description | Cinanserin hydrochloride is the hydrochloride salt of cinanserin, which is a 5-HT2 antagonist and an inhibitor of GPVI-mediated cell activation. It also acts as an inhibitor of CRP-XL- and collagen-induced Ca2+ release and aggregation. It is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus, and it strongly reduces virus replication in vitro. |
Product Information
Synonyms | Cinanserin HCl; Cinanserin Hydrochloride; SQ-10643; SQ 10643; SQ10643; NSC-125717; NSC 125717; NSC125717; (E)-N-[2-[3-(Dimethylamino)propylsulfanyl]phenyl]-3-phenylprop-2-enamide hydrochloride; N-[2-[[3-(Dimethylamino)propyl]thio]phenyl]-3-phenyl-2-propenamide Hydrochloride; MAPTC; SQ 10643; 2'-[[3-(Dimethylamino)propyl]thio]cinnamanilide Hydrochloride |
IUPAC Name | (E)-N-[2-[3-(dimethylamino)propylsulfanyl]phenyl]-3-phenylprop-2-enamide;hydrochloride |
Molecular Weight | 376.94 |
Molecular Formula | C20H25N2OSCl |
Canonical SMILES | CN(C)CCCSC1=CC=CC=C1NC(=O)C=CC2=CC=CC=C2.Cl |
InChI | InChI=1S/C20H24N2OS.ClH/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17;/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23);1H/b14-13+; |
InChIKey | LXGJPDKYMJJWRB-IERUDJENSA-N |
Boiling Point | 519.5°C at 760mmHg |
Flash Point | 268°C |
Purity | ≥99% by HPLC |
Solubility | In Vitro: DMSO : 125 mg/mL(331.62 mM;Need ultrasonic) H2O : 100 mg/mL(265.29 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution |
Appearance | Light yellow to yellow (Solid) |
Application | Serotonin Antagonists |
Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
In Vitro | Cinnacillin/ocnamicillin hydrochloride has binding affinity with SARS-CoV 3CLpro, HCoV-229e3clpro, and KDs of SARS-CoV 3CLpro and human coronavirus 229E are 49.4 μM/78.0 μM and 18.2 μM/36.6 μM, respectively. The IC50 values of cinacillin and cinnacillin hydrochloride inhibiting the catalytic activity of SARS-CoV 3CLpro were 4.92 μM and 5.05 μM, respectively, and the IC50 values of HCoV-229e3clpro were 4.68 μM and 5.68 μM, respectively, and no compound had an inhibitory effect on HRV-143CLpro in the 200 μM concentration range. |
PSA | 57.64000 |
Target | 5-HT Receptor; Influenza Virus |